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A double-headed cathepsin B inhibitor devoid of warhead
Abstract
Most synthetic inhibitors of peptidases have been targeted to the active site for inhibiting catalysis
through reversible competition with the substrate or by covalent modification of catalytic groups.
Cathepsin B is unique among the cysteine peptidase for the presence of a flexible segment, known as the
occluding loop, which can block the primed subsites of the substrate binding cleft. With the occluding
loop in the open conformation cathepsin B acts as an endopeptidase and as an exopeptidase when the
loop is closed. We have targeted the occluding loop of human cathepsin B at its surface, outside the
catalytic center, using a high-throughput docking procedure. The aim was to identify inhibitors that
would interact with the occluding loop thereby modulating enzyme activity without the help of chemical
warheads against catalytic residues. From a large library of compounds, the in silico approach identified
[2-[2-(2,4-dioxo-1,3-thiazolidin-3-yl)ethylamino]-2-oxoethyl] 2-(furan-2-carbonylamino)acetate, which
fulfils the working hypothesis. This molecule possesses two distinct binding moieties and behaves as a
reversible, double-headed competitive inhibitor of cathepsin B by excluding synthetic and protein
substrates from the active center. The kinetic mechanism of inhibition suggests that the occluding loop
is stabilized in its closed conformation, mainly by hydrogen bonds with the inhibitor, thus decreasing
endoproteolytic activity of the enzyme. Furthermore, the dioxothiazolidine head of the compound
sterically hinders binding of the C-terminal residue of substrates resulting in inhibition of the
exopeptidase activity of cathepsin B in a physiopathologically relevant pH range.
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Abstract 
Most synthetic inhibitors of peptidases have been targeted to the 
active site for inhibiting catalysis through reversible competition 
with the substrate or by covalent modification of catalytic groups. 
Cathepsin B is unique among the cysteine peptidase for the presence 
of a flexible segment, known as the occluding loop, which can block 
the primed subsites of the substrate binding cleft. With the 
occluding loop in the open conformation cathepsin B acts as an 
endopeptidase and as an exopeptidase when the loop is closed. We 
have targeted the occluding loop of human cathepsin B at its 
surface, outside the catalytic center, using a high-throughput 
docking procedure. The aim was to identify inhibitors that would 
interact with the occluding loop thereby modulating enzyme activity 
without the help of chemical warheads against catalytic residues. 
From a large library of compounds, the in silico approach identified 
[2-[2-(2,4-dioxo-1,3-thiazolidin-3-yl)ethylamino]-2-oxoethyl] 2-
(furan-2-carbonylamino)acetate, which fulfils the working 
hypothesis. This molecule possesses two distinct binding moieties 
and behaves as a reversible, double-headed competitive inhibitor of 
cathepsin B by excluding synthetic and protein substrates from the 
active center. The kinetic mechanism of inhibition suggests that the 
occluding loop is stabilized in its closed conformation, mainly by 
hydrogen bonds with the inhibitor, thus decreasing endoproteolytic 
activity of the enzyme. Furthermore, the dioxothiazolidine head of 
the compound sterically hinders binding of the C-terminal residue of 
substrates resulting in inhibition of the exopeptidase activity of 
cathepsin B in a physiopathologically relevant pH range. 
 
Abbreviations: Abz, ortho-aminobenzoyl; AMC, 7-amino-4-
methylcoumarin; DTT, dithiothreitol; Z, benzyloxycarbonyl; Dnp, Nε-
2,4-dinitrophenyl. FRET, Förster resonance energy transfer; DOFA [2-
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[2-(2,4-dioxo-1,3-thiazolidin-3-yl)ethylamino]-2-oxoethyl] 2-(furan-
2-carbonylamino)acetate; MALDI, matrix-assisted laser 
desorption/ionization; MS, mass spectrometry; LC, liquid 
chromatography; SDS-PAGE, sodium dodecyl sulphate, polyacrylamide 
gel electrophoresis. 
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Cathepsin B, a cysteine peptidase of the papain family [EC 3.4.22.1, 
identifier C01.060 in the Merops Database (Rawlings et al. 2004)], 
has been classically ranked among the lysosomal enzymes and 
implicated in intracellular protein digestion. Physiologically, 
cathepsin B is also involved in antigen processing (Matsunaga et al. 
1993), in the activation of thyroglobulin, the precursor of thyroid 
hormones (Friedrichs et al. 2003), and in the maturation of beta-
galactosidase (Okamura-Oho et al. 1997). From a pathological point 
of view cathepsin B activates trypsinogen in hereditary pancreatitis 
(Kukor et al. 2002), participates in apoptosis (Bröker et al. 2005), 
tumor progression and malignancy (Yan and Sloane 2003; Mohamed and 
Sloane 2006), and rheumatic diseases (Lenarcic et al. 1988; Baici et 
al. 1995a; Baici et al. 1995b). Particular extralysosomal functions 
of cathepsin B are due to altered expression at the gene level 
and/or atypical trafficking (Müntener et al. 2003; Zwicky et al. 
2003; Müntener et al. 2004; Baici et al. 2006). 
Cathepsin B is capable of endopeptidase (Mort 2004), peptidyl-
dipeptidase (Aronson and Barrett 1978; Bond and Barrett 1980) and 
carboxypeptidase activities (Takahashi et al. 1986; Rowan et al. 
1993). Among the cysteine peptidases it owns a unique structural 
element, called occluding loop, which comprises residues Ile105-Pro126 
(Musil et al. 1991) (Figure 1). At low pH two salt bridges, His110-
Asp22 and Arg116-Asp224, hold the loop in a closed position over the 
primed subsites of the substrate binding cleft thus preventing 
extended binding of polypeptides and endoproteolytic activity. The 
closed conformation, through the engagement of His111 in a hydrogen 
bond with the C-terminal carboxylate of the substrate and the loose 
specificity in P2', is responsible for the peptidyl-dipeptidase 
activity of cathepsin B (Illy et al. 1997; Quraishi et al. 1999; 
Krupa et al. 2002). As mutations of the amino acids His110 and Asp22 
have shown, removal of the salt bridges induces endopeptidase 
activity, attributed to increased flexibility of the loop (Nägler et 
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al. 1997). This concept agrees with higher endopeptidase activity 
and with the competition between the occluding loop and the 
propeptide following deprotonation of His110 changing the pH from 4.0 
to 6.0 (Quraishi et al. 1999). The flexibility of the loop was 
further demonstrated by the fact that cystatins A and C were able to 
displace the loop (Nycander et al. 1998; Pavlova et al. 2000), and 
deletion of residues 108-119 abolished the exopeptidase activity of 
cathepsin B (Illy et al. 1997). 
A large number of synthetic compounds behave as inhibitors of 
cathepsin B. Most of them are either reversible or irreversible 
competitive inhibitors acting 'inside the active center' (Otto and 
Schirmeister 1997; Michaud and Gour 1998; Frlan and Gobec 2006). The 
practical use of these inhibitors is in most cases difficult for 
reasons analyzed elsewhere (Baici 1998). In the present study we 
target cathepsin B 'from the outside', i.e. at the surface of the 
molecule excluding any direct interference with catalysis. Our 
strategy aims at proving the concept that latching the occluding 
loop in its closed conformation may possibly hinder the endo- and/or 
exopeptidase activities of the enzyme. The approach consists in 
computational analysis by docking a large number of compounds to the 
surface of cathepsin B in the occluding loop region. From 40 
compounds matching the working hypothesis, 29 are commercially 
available and one of them inhibits at low micromolar concentration 
the endo- and exoproteolytic activities of cathepsin B. We analyze 
the kinetic mechanism of inhibition, from which we propose a model 
for the interaction between the compound and the enzyme. 
Results 
Kinetic mechanism of inhibition with synthetic substrates 
Z-RR↓AMC and Abz-GIVR↓AK(Dnp)-OH were used as substrates for 
monitoring the endo- and exoproteolytic activity of cathepsin B, 
respectively. Arrows in the substrate acronyms indicate the scissile 
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bonds. Forty of 47878 compounds screened in the docking approach 
were selected as candidate binders of human cathepsin B. Twenty-nine 
of them were commercially available, were tested as modifiers of 
enzyme activity, and one of them, DOFA (Figure 2), behaved as a true 
inhibitor. Two compounds out of twenty-nine were scarcely soluble in 
DMSO (Zinc 20005-codes 1271923 and 2990182, Supplemental Table 1). 
Five of them were soluble in DMSO but were prone to aggregation 
under the assay conditions for cathepsin B giving rise to modest and 
inconsistent inhibition between different assays. We considered 
these five compounds (958753, 1837733, 1871954, 3247330 and 1581881) 
as promiscuous inhibitors (Shoichet 2006). None of the compounds 
tested was a covalent inactivator of cathepsin B. DOFA did not 
inhibit human cathepsin L and papain was only partially inhibited at 
millimolar concentrations (assays with Z-FR↓AMC, data not shown). A 
previous report of high throughput screening classified DOFA 
inactive against cathepsin B (http://pubchem.ncbi.nlm.nih.gov/, CID 
2078629, AID 453). Reasons can be searched in either too strict 
criteria or in the occasional failure of high throughput screening 
methods in detecting hits (Buxser and Vroegop 2005). DOFA behaved as 
a reversible inhibitor of cathepsin B and did neither manifest 
tight-binding nor slow-binding inhibition behavior. Reaction traces 
were linear from the very beginning of the reaction, i.e. from 3-4 
ms onwards, as measured with a stopped-flow apparatus. Therefore, 
initial velocities at variable substrate and modifier concentrations 
were treated as steady-state rates. In control experiments we 
checked the possibility that any inhibitory effect of DOFA was not 
due to aggregation of the compound. For this purpose 0.01% Triton 
was added to buffers and the DTT concentration was increased to 5 
mM. In comparison with buffer not containing detergent and with DTT 
= 2 mM, the basal activity of cathepsin B was higher by about 40%. 
However, inhibition profiles for increasing DOFA concentration, 
percentages of inhibition and inhibition constants were the same. 
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The kinetic results in this study refer to those obtained with the 
enzyme purified from human liver. Nevertheless, we confirmed 
inhibition mechanisms and kinetic parameters also with recombinant 
cathepsin B. The reason was to ascertain any influence of 
glycosylation at N113, which is located at the tip of the occluding 
loop, on the binding of potential inhibitors. Both kinetic and 
modeling results discussed below suggest that N113 glycosylation 
possibly occurring in the wild type enzyme does not affect 
inhibition of cathepsin B by DOFA. 
The kinetic mechanism was analyzed by a combination of graphical and 
regression methods to discriminate between models of enzyme-modifier 
interaction (Figure 3). With the Abz-GIVR↓AK(Dnp)-OH exoproteolytic 
substrate at pH 4.5 the best fitting model for cathepsin B 
inhibition by DOFA was linear competitive inhibition with I90/10 = 81 
and Ki = 6.7 µM (Figure 4A). The specific velocity plot, typical for 
this mechanism, is shown in the inset of Figure 4A. With this 
substrate, data at pH 6.0 could not be obtained because of its 
scarce solubility. DOFA inhibited the endoproteolytic cathepsin B 
activity (Z-RR↓AMC as substrate) at pH 4.5 and 6.0. The specific 
velocity plot (not shown) established the linear nature of the 
inhibition process, i.e. enzyme activity was driven to zero at 
saturating inhibitor concentration, and diagnosed competitive-type 
inhibition. However, the specific velocity plot would not be able to 
discriminate between Models 1-3 in Figure 3. The activity profiles 
obtained at a fixed substrate concentration and variable inhibitor 
concentrations revealed the I90/10 ratio to be less than 81, which can 
be estimated by inspection to be around 60 at pH 4.5 and around 40 
at pH 6.0 (Figure 4B). This suggests that the inhibition mechanism 
was not of the classical competitive type, for which I90/10 = 81 (Model 
1 in Figure 3). On the other hand, models 2 and 3 in the same figure 
predict I90/10 values less than 81. For discriminating between models 
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with Z-RR↓AMC as substrate we set its concentration equal to K
m
 so 
that σ = [S]/K
m
 = 1 in the activity profiles in Figure 4B (thereby it 
was imperative to carefully measure the substrate concentration and 
K
m
). In models 2 and 3, when the factor a = 1, I90/10 depends only on 
σ, whereas for a ≠ 1 the I90/10 ratio depends both on a and σ (Figure 
5A, B). Model 2 was ruled out as redundant, and model 3 was 
preferred on the basis of the following quantitative and logical 
observations. In model 2, two inhibitor molecules should bind to 
different places at the surface of the cathepsin B molecule with 
almost the same affinity, i.e. with the a-value between 1 and 2, as 
shown in Figure 5A. The double-headed inhibitor (model 3 in Figure 
3) was superior also on the basis of the following quantitative 
observations. For model 3, the squared symbol with dashed arrows in 
Figure 5 indicates the best-fit value for a = 6 at pH 6.0, which 
corresponds to I90/10 = 37 and Ki = 11.3 µM (Figure 4B). Similarly, at 
pH 4.5, model 3, with a = 34 (the black circle in Figure 5B), I90/10 = 
59 and Ki = 4.8 µM, produced a better fit to experimental data than 
model 2 (Figure 4B). 
Inhibition of endo- and exoproteolysis using protein substrates 
While low molecular mass oligopeptides are indispensable tools for 
determining inhibition mechanisms, they do not represent typical 
substrates for evaluating true endo- and exoproteolytic activities. 
Therefore, inhibition of cathepsin B endo- and exoproteolysis by 
DOFA was further investigated with two protein substrates: rabbit 
muscle aldolase and the oxidized β-chain of bovine insulin. Peptide 
bond hydrolysis on both proteins at pH 6.0 was inhibited in a 
concentration dependent manner by DOFA (Figure 6) and was almost 
complete at saturating inhibitor concentration. As commonly observed 
when switching from oligopeptide to polypeptide substrates, the 
modifier concentrations needed for achieving inhibition were higher. 
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Cathepsin B has been previously reported to sequentially remove up 
to nine dipeptide units from the C-terminus of aldolase with 
peptidyl-dipeptidase activity (Bond and Barrett 1980). Aldolase 
incubated with cathepsin B in the presence or not of DOFA was 
subjected to SDS-PAGE under reducing conditions. The bands excised 
after electrophoretic separation were N-terminally sequenced and the 
masses of the polypeptides determined by mass spectrometry. The SDS 
gels shown in Figure 7 were purposely overloaded to reveal the less 
prominent bands numbered 2, 3 and 4. The N-terminal sequence of the 
polypeptides in bands 1 and 2 was PHSHPAL, which corresponds to 
positions 2-8 of aldolase. Mass analysis of the whole broad band 1 
revealed the presence, besides intact aldolase with amino acids 2-
364 and a mass of 39216 Da, C-terminally degraded fragments 
corresponding to sequences 2-362, 2-360, and other masses down to 2-
352 that were generated by the sequential removal of six dipeptide 
units from the C-terminus. The significant presence of the 2-351 
peptide indicates that aldolase degradation also comprises 
carboxypeptidase activity of cathepsin B. The tiny band 2 contained 
the polypeptide 2-347, which was the smallest fragment obtained 
under the described conditions and corresponded to the removal of 17 
amino acids from the C-terminus, i.e. 8 dipeptide units (peptidyl-
dipeptidase activity) plus one amino acid (carboxypeptidase 
activity). Bands 3 and 4 had the common N-terminus SIGTENT 
(positions 46-52) suggesting their generation by a minor (but very 
useful for the purposes of this test) endoproteolytic cleavage 
between Gln45 and Ser46. Band 3 corresponded to the 46-364 sequence 
and band 4 corresponded to sequence 46-347. Comparison of the 
relative intensities of bands 3 and 4 in lanes B and C (Figure 7) 
suggests that DOFA inhibited the exopeptidase activity of cathepsin 
B on the macromolecular substrate aldolase, while the inhibitor was 
less or not active against the endoproteolytic activity of cathepsin 
B, as shown by the persistence of band 3 in lane C. 
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The bovine insulin β-chain is a helpful substrate for exploring the 
specificity of peptide bond cleavage by peptidases, including human 
cathepsin B (McKay et al. 1983). The cleavage at multiple sites of 
the insulin β-chain by cathepsin B was almost completely inhibited 
by a saturating concentration of DOFA at pH 6.0 (Figure 6). Samples 
of insulin β-chain incubated with cathepsin B in the presence and 
absence of DOFA were separated by liquid chromatography and the 
eluted peaks were analyzed by mass spectrometry. We confirmed most 
of the cathepsin B cleavages previously described (McKay et al. 
1983). Additional cleavages, which depended on the incubation time 
and the relative enzyme to substrate concentrations, were 
identified. Each of the chromatographic peaks in Figure 8 contained 
only one (e.g. peptides 1-13, 1-14 and 6-28) or more proteolytic 
fragments (e.g. peptides 20-30 plus 1-11). Only a few of them will 
be commented to demonstrate the inhibitory activity of DOFA. The 
generation of peptides 1-11 and 20-30 by endoproteolysis was 
inhibited by DOFA. Fragment 1-13 was a product of carboxypeptidase 
activity on peptide 1-14: while DOFA completely inhibited this 
exoproteolytic event, endoproteolytic cleavage between residues 14 
and 15 was unaffected, as shown by comparing the chromatographic 
profiles in the absence (Figure 8A) and in the presence of DOFA 
(Figure 8B). Fragment 18-29, generated by endoproteolysis at 
position 17-18 and carboxypeptidase exoproteolysis at position 29-
30, was strongly decreased in the presence of DOFA. Comparison of 
the areas of fragments 18-29 and 18-30 after inhibition shows that 
both the exo- and the endoproteolytic events concerned with them 
were affected by the inhibitor. Carboxypeptidase activity inhibition 
is also shown by comparing the disappearance of fragment 16-29 and 
the appearance of fragment 16-30. Finally, the peptidyl-dipeptidase 
cleavage shown by fragment 6-28 disappeared in the presence of DOFA. 
Since the 6-30 peptide in Figure 8B could not be unambiguously 
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assigned, inhibition could be ascribed to endoproteolytic cleavage 
at positions 5-6, peptidyl-dipeptidase inhibition at position 28-29, 
or both. 
Discussion 
The docking approach used in this study aimed at identifying 
compounds that bind to the occluding loop of human cathepsin B and 
thereby modulate its enzymatic activity. Considering that no other 
means are available for selecting small molecules for a rather 
flexible protein segment, the most diverse compound library was 
used. There is a fundamental difference between our methodology and 
previous approaches to inhibitors that might interact with parts of 
the occluding loop of cathepsin B (Murata et al. 1991; Michaud and 
Gour 1998; Cathers et al. 2002). These studies exploited the 
properties of the fungal inhibitor E-64 (Hanada et al. 1978) and the 
crystal structure of cathepsin B (Musil et al. 1991). New 
inhibitors, such as CA-074, were designed by modification of the E-
64 structure to create interactions with the primed sites of the 
substrate binding cleft and thus with the occluding loop (Murata et 
al. 1991). In this approach the epoxy moiety of the modifiers acted 
as a warhead against the active site cysteine to produce potent 
irreversible inhibition (Matsumoto et al. 1999). Conversely, we did 
not target the active site and the molecules selected by docking 
were devoid of chemically active warheads. The finding of only one 
active compound out of 29 substances is in line with previous 
studies, which showed that candidate inhibitors predicted by docking 
algorithms are not necessarily active in vitro (Huang et al. 2005). 
In agreement with published data (Illy et al. 1997; Nägler et al. 
1997; Quraishi et al. 1999; Krupa et al. 2002) our results support 
the notion that the occluding loop of cathepsin B is a highly 
flexible segment. Short episodes of opening and closing govern endo- 
and exoproteolysis, which thus occur intermittently in the pH range 
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4.5-6.0. The compound identified by docking, DOFA, behaves as a 
reversible competitive inhibitor of the exo- and endopeptidase 
activities of cathepsin B with no involvement of a substrate-like 
binding mode in the active center of the enzyme. It can inhibit 
endoproteolysis most likely by forcing the loop in the closed 
conformation and exoproteolysis by disturbing the accommodation of 
the C-terminus of polypeptides in the primed side of the binding 
cleft. Docking calculations suggest that the dioxothiazolidine 
moiety of DOFA is located in the binding pocket of the side chain of 
the substrate C-terminal residue when the loop is closed. It makes a 
hydrogen bond with Nδ1 of His110 and sterically hinders substrate 
binding for exoproteolytic activity (Figure 9A, B). In this figure, 
the structures of DOFA and the four amino acids VRAK, which are part 
of the FRET substrate used for measuring exoproteolytic activity, 
were modeled on the known structure of human cathepsin B merely to 
show their spatial relationship. In fact, such a ternary ESI complex 
does not exist according to the kinetic mechanism, only the ES and 
EI complexes exist. This structural arrangement is consistent with 
the kinetic mechanism of inhibition: at pH 4.5 the exoproteolytic 
activity of cathepsin B is inhibited in a linear competitive manner 
by virtue of the dioxothiazolidine ring. Docking suggests that DOFA 
binds at the surface of the occluding loop and is involved in three 
hydrogen bonds with the enzyme (Figure 9A). Of particular interest 
is that the carbonyl oxygen involved in a hydrogen bond with the 
amide of His111 occupies the place of the oxygen of a conserved water 
molecule present in the crystal structures of human cathepsin B. 
This position is shown as a red sphere in Figure 9B. Together with 
the favorable van der Waals interactions three hydrogen bonds 
stabilize the loop in the closed conformation (Figure 9B). These 
structural properties are reflected in the kinetic mechanism 
observed with Z-RR↓AMC. Despite not being a complete model for 
endoproteolysis, the dipeptide is unquestionably cleaved by 
 - 13 - 
cathepsin B in the endo-, not in the exoproteolytic mode. The 
double-headed, competitive kinetic mechanism diagnosed for DOFA on 
Z-RR↓AMC, and the changes in the kinetic parameters observed when 
going from pH 4.5 to 6.0, insinuate cooperation between the furan 
and the dioxothiazolidine moieties. Kinetic measurements alone would 
be unable to identify which element makes the stronger contribution 
to binding energy. However, with the support of structural 
information from modeling discussed above, we suggest that the 
dioxothiazolidine moiety takes the leader function. In the double-
headed mechanism at pH 4.5, the Ki-value of 4.8 µM is thus ascribed 
to the dioxothiazolidine part of the molecule and Ki ≈ 160 µM to the 
furan part (factor a = 34 in Model 3, Figure 3). The increase of pH 
to 6.0 disfavors the Ki of the dioxothiazolidine portion, which 
becomes 11.3 µM, and favors binding of the furan moiety decreasing 
its Ki to 68 µM. 
The measurements with protein substrates, aldolase and the insulin 
β-chain, confirm the results just discussed with synthetic 
substrates, as well as the previously recorded ability of cathepsin 
B to exert peptidyl-dipeptidase and carboxypeptidase activity in the 
pH range 5.5-6.0 (Mort et al. 1998). While efficiently inhibiting 
these two exoproteolytic activities, DOFA was not able to inhibit 
all endoproteolytic events. For instance, the minor endoproteolytic 
action at position 45-46 of rabbit muscle aldolase was only 
moderately or not affected by DOFA, as was not position 14-15 of the 
insulin β-chain. Yet, other endoproteolytic attacks on the insulin 
β-chain were efficiently inhibited. 
The pooled experimental evidence from the above described properties 
of DOFA inhibition strengthens the notion that not only pH-
dependent, intermittent closing and opening of the occluding loop, 
but also substrate structure determine together the susceptibility 
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of particular peptide bonds. The binding affinity of DOFA is 
possibly not high enough to compete with a substrate, which 
optimally binds at both unprimed and primed sites. It appears that 
the occluding loop of cathepsin B can be assisted in assuming its 
close or open conformation by particular polypeptides with an 
induced fit mechanism that promotes either exo- or endoproteolysis. 
This observation forms the basis of cathepsin B inhibition by the 
own propeptide (Quraishi et al. 1999) and its reluctance to cystatin 
A and C inhibition (Nycander et al. 1998; Pavlova et al. 2000). 
The above results draw attention to the physiopathological role of 
cathepsin B, which exerts its action in a relatively broad range of 
pH values, with exoproteolysis in the range 5-6 and endoproteolysis 
in the range 5-7.4. The pH in early endosomes is about 6.2 and drops 
to 5.0-5.5 in late endosomes and lysosomes (Gu and Gruenberg 2000). 
Extracellularly, the pH can vary from relatively acidic, e.g. at the 
periphery of solid tumors (Rofstad et al. 2006), to 7.4 in blood. 
Contrary to commonplace textbook information, proteolysis within 
phagolysosomes does not quite occur in a very acidic environment. 
For instance, 5 min after initiation of phagocytosis in human 
polymorphonuclear leukocytes, the relatively acidic milieu of the 
lysosomes (pH ≈ 5) increases in the phagocytic vacuoles to a value 
of 7.8. It falls then to 7.4 after 15 min, to 6.4 after 30 min and 
5.7 after 60 min [rounded values from (Cech and Lehrer 1984)]. 
Various hydrolases are expected to find their optimal conditions of 
action during this forth and back excursion of pH (Baici et al. 
1996). 
It has been suggested that 'targeting of the occluding loop of 
cathepsin B may be a poor inhibitor design strategy if the enzyme 
environment has a pH greater than 5.5' (Cathers et al. 2002). This 
statement refers to the above discussed approach 'from inside'. 
Since endo- and exoproteolysis by cathepsin B occurs in the 
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physiologically and pathologically relevant pH range of 5-6, our 
approach of targeting the occluding loop from the enzyme surface may 
represent an alternative starting point for the development of 
clinically active compounds. 
Materials and methods 
Materials and general methods 
Recombinant human cathepsin B was prepared from E. coli inclusion 
bodies (Kuhelj et al. 1995). Wild type cathepsin B from human liver 
was obtained from Calbiochem (Nottingham, England). The synthetic 
substrates Z-FR↓AMC2 and Z-RR↓AMC were purchased from Bachem 
(Bubendorf, Switzerland), and the internally quenched fluorogenic 
substrate Abz-GIVR↓AK(Dnp)OH from Merck (Nottingham, England). 
Rabbit muscle fructose-1,6-bisphosphate aldolase (EC 4.1.2.13) and 
fluorescamine were from Sigma-Aldrich Chemie (Buchs, Switzerland) 
and the oxidized bovine insulin β-chain from Serva Feinbiochemica 
(Heidelberg, Germany). The putative binders/modifiers of cathepsin B 
activity determined by docking analysis and their sources are listed 
in supplemental Table 1. The compound studied in detail, [2-[2-(2,4-
dioxo-1,3-thiazolidin-3-yl)ethylamino]-2-oxoethyl] 2-(furan-2-
carbonylamino)acetate (IUPAC name, here abbreviated DOFA, Figure 2), 
Zinc-2005 code 2616818 (Irwin and Shoichet 2005) was obtained from 
Enamine (Kiev, Ukraine). The compounds were dissolved as 
concentrated stock solutions in dimethyl sulphoxide, stored at 4°C 
and diluted into the appropriate buffer at the moment of the assay. 
Photometric measurements were carried out with a Cary50 UV-visible 
spectrophotometer and fluorescence was measured with an Aminco SPF-
500 fluorimeter operating in the ratio mode. Reversed phase HPLC was 
performed in a Hewlett Packard Series 1100 apparatus with a 
Nucleosil 120-5 C18 column (4.0 x 250 mm). Matrix-assisted laser 
desorption/ionization mass spectrometry (MALDI-MS) and liquid-
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chromatography followed by mass analysis, LC-MALDI/MS, was performed 
at the Functional Genomics Center in Zurich. 
Docking 
The A and B chains of the human cathepsin B structure, entry 1HUC in 
the Brookhaven database, were considered and all water molecules 
were removed. Hydrogens were added to side chains and termini of the 
protein to simulate conditions at pH 6-7. Cys29 was in the reduced 
form and His110 was protonated at both imidazole nitrogen atoms. 
CHARMm atom types and force field parameters were assigned and used 
for both protein and ligands (Momany and Rone 1992), and hydrogens 
were minimized with the program CHARMM (Brooks et al. 1983). The 
search for a putative binding site focused on the occluding loop of 
the enzyme, for which no inhibitor has been reported to date. A 
benzene molecule was used as a probe with the program SEED 
(Solvation Energy for Exhaustive Docking) to identify possible 
binding pockets whose main interaction component is supposed to be 
hydrophobicity (Majeux et al. 1999). The surface tested by SEED 
consists of Cathepsin B residues within a 9 Å distance from His110, 
which locks the occluding loop in a closed position. The benzenes 
with the most favorable free energy of binding, excluding those in 
the catalytic site, were used to define the binding site for 
docking, which included all the 42 residues of the protein that had 
more than 50% of their atoms within 5 Å distance from the optimal 
poses of benzenes. 
About 3 million compounds in the ZINC 2005 library (Irwin and 
Shoichet 2005) were clustered using a 17-field fingerprint by DAIM 
(Decomposition and Identification of Molecules) (Kolb and Caflisch 
2006). Molecules with more than nine rotatable bonds were neglected. 
The resulting 48026 cluster representatives were docked as in 
previous in silico campaigns (Huang et al. 2005; Huang et al. 2006; 
Kolb et al. 2008). For each molecule docked by the program FFLD 
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(Fragment-based Flexible Ligand Docking) (Budin et al. 2001; 
Cecchini et al. 2004), the 300 most favorable poses were clustered 
with the leader algorithm yielding 764776 poses (~17 poses per 
compound, 44527 compounds). The cluster representatives were 
minimized in the rigid protein using CHARMM. 
It is necessary to weed out unlikely poses to prevent a high number 
of false positives (Kolb et al. 2008). Suitable filters are cutoffs 
in the total van der Waals interaction energy and in the van der 
Waals efficiency (defined as the ratio between van der Waals energy 
and molecular mass). A cutoff of −30 kcal/mol for intermolecular van 
der Waals energy was selected by plotting a histogram of the van der 
Waals energies (supplemental Figure 1). Analogously, a cutoff of 
−0.09 kcal/g was chosen for the van der Waals efficiency 
(supplemental Figure 2). A total of 106502 poses of 10709 compounds 
survived both filters. Poses closer than 4 Å to Cys29 of the 
catalytic site, and those with no hydrogen bond to the protein were 
neglected yielding 25178 remaining poses (5678 compounds). 
The electrostatic contribution to the binding free energy was 
evaluated by the finite difference Poisson approach (module PBEQ of 
CHARMM) (Im et al. 1998). Poses were ranked for visual inspection 
according to most favorable van der Waals energy, van der Waals 
efficiency, electrostatics, and sum of van der Waals and 
electrostatic energy. Poses with high ranking in two lists or more 
were selected and visually inspected. Forty poses belonging to 40 
different compounds were selected in this way. According to the 
predicted binding modes, three regions of the protein were exploited 
for binding: one on the occluding loop and one each on immediately 
adjacent regions. Twenty-nine out of the 40 candidate compounds were 
commercially available. 
Kinetics 
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The peptide Z-RR↓AMC with 7-amino-4-methlycoumarin (AMC) as leaving 
group is a handy substrate for measuring the endopeptidase activity 
of cathepsin B (Barrett 1980), in which the two arginine residues 
correspond to the P1 and P2 positions (Schechter and Berger 1967). We 
preferred this substrate over Z-FR↓AMC for its slower hydrolysis 
that allowed long measuring times with low substrate consumption. 
The buffer for measurements at pH 6.00 was 50 mM sodium phosphate 
containing 2 mM EDTA and 2 mM dithiothreitol (DTT), thereafter 
referred to as pH 6.0-buffer. For measurements at pH 4.50, 0.1 M 
sodium acetate, 0.2 M NaCl, 2 mM EDTA and 2.5 mM DTT was used 
(thereafter referred to as pH 4.5-buffer). In control experiments 
aimed at ascertaining any aggregation phenomena on the part of the 
putative inhibitors, the DTT concentration was increased to 5 mM and 
the buffer included 0.01% w/v of hydrogenated Triton X-100, which 
does not absorb light in the ultraviolet range and is not 
fluorescent. The buffers were prepared and used at the same 
temperature of the kinetic assays, 25 ± 1°C. The final concentration 
of dimethyl sulphoxide, used for preparing stock solutions of the 
compounds, was 0.2% v/v in experiments with synthetic substrates and 
1% v/v in those with protein substrates. Reaction progress with Z-
RR↓AMC at pH 4.5 and 6.0 was followed by either measuring the change 
in absorbance at 360 nm, with ∆ε = 11,400 M−1cm−1 as the difference 
absorption coefficient between free and bound AMC, or 
fluorimetrically with excitation and emission wavelengths, λ
ex
 and 
λ
em
, set at 383 and 455 nm, respectively. Exopeptidase activity was 
continuously monitored fluorimetrically with the Förster resonance 
energy transfer (FRET) labeled substrate Abz-GIVR↓AK(Dnp)-OH (Cotrin 
et al. 2004). Appropriate corrections for inner filter effects were 
taken into account in fluorescence measurements considering the 
absorbances of the substrates and of the tested compounds at λ
ex
 and 
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λ
em
 (Palmier and Van Doren 2007). With the AMC-based substrate, λ
ex
 at 
383 nm allowed high substrate concentrations to be used with small 
inner filter corrections. Since with the FRET substrate inner filter 
effects were more pronounced, λ
ex
 and λ
em
 were selected according to 
the compound being tested. The combination λ
ex
/λ
em
 320/420 nm, often 
used in assays with this type of substrates, could not be utilized 
for the strong absorbance at 320 nm of one of the compounds (ZINC-
2005 code 1797383), which simulated strong enzyme inhibition, 
whereas the combination λ
ex
/λ
em
 370/430 nm revealed no inhibition. Any 
modifier-independent contribution to enzyme activity loss by 
denaturation, adherence to the vessel walls or other causes was 
monitored in time-course assays by the Selwyn method (Selwyn 1965). 
Screening and primary analysis of the kinetic inhibition mechanism 
of the compounds was performed on initial velocity data obtained at 
various concentrations of substrate and compounds. The specific 
velocity plot, a sensitive tool for detecting mixed-type and/or 
hyperbolic mechanisms was routinely used in this phase (Baici 1981). 
The kinetic inhibition models considered and their related rate 
equations are shown in Figure 3. In Models 2 and 3, a is a 
coefficient, which is equal to 1 when the first binding process does 
not influence the second one. If the equilibrium constant of the 
vacant site is influenced after binding to the first site a ≠ 1. 
Kinetic analysis was performed by fitting the equations in Figure 3 
to experimental data using GraphPad Prism version 5.00 for Windows, 
GraphPad Software, San Diego California USA, www.graphpad.com. The 
runs test and analysis of residuals were performed to monitor 
deviations from a model and discrimination between mechanisms was 
made by analysis of variance of the difference between the sum of 
squares (extra sum-of-squares test) and calculation of F ratios and 
p values. According to the Occam's razor principle, the simplest 
mechanism describing experimental data was considered superior to a 
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more complex (redundant) mechanism. Additionally, a powerful and 
decisive tool for model discrimination was the I90/10 ratio, i.e. the 
ratio of inhibitor concentration necessary to achieve 90% and 10% 
inhibition. This parameter was determined experimentally and 
compared with values calculated from equations 4 and 6 in Figure 3. 
Protein substrates 
The activity of cathepsin B on rabbit muscle aldolase was quantified 
by measuring primary amino groups derived from peptide bond 
hydrolysis with fluorescamine (Schwabe 1975). Aldolase was dissolved 
in pH 6.0-buffer without DTT, incubated 3 h at 37°C with cathepsin 
B, which was pre-activated with DTT, and DOFA under vigorous shaking 
to prevent precipitation. Final concentrations were: aldolase = 3.5 
mg/mL = 21.7 µM, cathepsin B = 2.3 µM, DOFA = 0.5, 1.0, 1.5 and 2.0 
mM. The reaction was stopped with trichloroacetic acid, 5% (w/v) 
final concentration, and centrifuged. 0.1 mL of the clear 
supernatant was added to 2.0 mL 0.2 M sodium borate buffer, pH = 
8.50, and 1.0 mL of fluorescamine solution (15 mg/100 mL acetone). 
The fluorescence of labeled peptides was measured with λ
ex
/λ
em
 = 
390/480 nm. Blanks were subtracted and controls compared with the 
samples containing the compounds. Measurements with the oxidized β-
chain of bovine insulin as substrate were performed in pH 6.0-buffer 
using the same procedure. Final concentrations were: insulin β-chain 
= 72 µg/mL = 20.6 µM, cathepsin B = 2.3 µM, DOFA = 0.5, 1.0, 1.5 and 
2.0 mM. 
Endo- and exoproteolysis of protein substrates 
Reaction products resulting from incubation of aldolase with 
cathepsin B and DOFA were also assessed by denaturing gel 
electrophoresis. Final concentrations in incubation mixtures at 25°C 
under continuous shaking for 4 h were: aldolase 3.5mg/mL (21.7 µM) 
in pH 6.0-buffer without DTT, 2.3 µM of pre-activated cathepsin B 
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and 1.0 mM DOFA. After centrifugation, the clear supernatant was 
analyzed by sodium dodecyl sulphated, polyacrylamide gel 
electrophoresis (SDS-PAGE) under reducing conditions with 12.5% 
polyacrylamide and silver stained. For N-terminal sequencing by 
Edman degradation, the bands were transferred to a polyvinylidene 
fluoride membrane. Peptides in the excised bands were also 
identified by MALDI analysis. 
The oxidized β-chain of bovine insulin was incubated at a final 
concentration of 1.0 mg/mL (286 µM) in 0.1 M sodium acetate buffer 
containing 0.2 mM NaCl, 2 mM EDTA and 2.5 mM DTT, pH = 5.50 with 1.2 
µM cathepsin B (control) or cathepsin B plus 1.0 mM DOFA. After 20 h 
at 25°C under shaking, solutions were centrifuged and the solvent 
removed in a Speed Vac concentrator. The residue was resuspended in 
60 µL of deionized water containing 0.1% trifluoroacetic acid and 
centrifuged before analysis by LC/MALDI/MS. 
Electronic supplemental material 
Supplemental Table 1 shows the identification codes and the sources 
of the cathepsin B inhibitors. Supplemental Figure 1 presents the 
Van der Waals interaction energies distribution used in the docking 
procedure and shows the cutoff of −30 kcal/mol for intermolecular 
van der Waals energy. Analogously, supplemental Figure 2 shows the 
Van der Waals interaction energy efficiencies distribution. 
Acknowledgments 
Docking calculations were performed on Matterhorn, a Beowulf Linux 
cluster at the University of Zurich, and we thank C. Bolliger, T. 
Steenbock, and A. Godknecht for computer support. We thank A. Widmer 
(Novartis Pharma, Basel, Switzerland) for providing the molecular 
modeling program Wit!P, which was used for preparing the structures. 
We also thank the staff at the Functional Genomics Center in Zurich 
for expert assistance in LC/MALDI/MS measurements. This work was 
 - 22 - 
supported by grant 31-113345/1 of the Swiss National Foundation and 
by the Albert-Böni Foundation (to A. Baici), and by a grant of the 
Hartmann-Müller Foundation (to A. Caflisch). 
 
Conflict of interest statement 
 
We declare that there are no conflicts of interest regarding 
this manuscript. 
 
 - 23 - 
References 
Aronson, N.N., Jr., and Barrett, A.J. 1978. The specificity of 
cathepsin B. Hydrolysis of glucagon at the C-terminus by 
a peptidyldipeptidase mechanism. Biochem. J. 171: 759-
765. 
Baici, A. 1981. The specific velocity plot. A graphical method 
for determining inhibition parameters for both linear and 
hyperbolic enzyme inhibitors. Eur. J. Biochem. 119: 9-14. 
Baici, A. 1998. Inhibition of extracellular matrix-degrading 
endopeptidases: Problems, comments, and hypotheses. Biol. 
Chem. 379: 1007-1018. 
Baici, A., Hörler, D., Lang, A., Merlin, C., and Kissling, R. 
1995a. Cathepsin B in osteoarthritis: zonal variation of 
enzyme activity in human femoral head cartilage. Ann. 
Rheum. Dis. 54: 281-288. 
Baici, A., Lang, A., Hörler, D., Kissling, R., and Merlin, C. 
1995b. Cathepsin B in osteoarthritis: cytochemical and 
histochemical analysis of human femoral head cartilage. 
Ann. Rheum. Dis. 54: 289-297. 
Baici, A., Müntener, K., Willimann, A., and Zwicky, R. 2006. 
Regulation of human cathepsin B by alternative mRNA 
splicing: homeostasis, fatal errors and cell death. Biol. 
Chem. 387: 1017-1021. 
Baici, A., Szedlacsek, S.E., Früh, H., and Michel, B.A. 1996. 
pH-dependent hysteretic behaviour of human myeloblastin 
(leucocyte proteinase 3). Biochem. J. 317: 901-905. 
Barrett, A.J. 1980. Fluorimetric assays for cathepsin B and 
cathepsin H with methylcoumarylamide substrates. Biochem. 
J. 187: 909-912. 
Bond, J.S., and Barrett, A.J. 1980. Degradation of fructose-
1,6-bisphosphate aldolase by cathepsin B. A further 
example of peptidyldipeptidase activity of this 
proteinase. Biochem. J. 189: 17-25. 
Bröker, L.E., Kruyt, F.A.E., and Giaccone, G. 2005. Cell death 
independent of caspases: A review. Clin. Cancer Res. 11: 
3155-3162. 
Brooks, B.R., Bruccoleri, R.E., Olafson, B.D., States, D.J., 
Swaminathan, S., and Karplus, M. 1983. CHARMM: a program 
 - 24 - 
for macromolecular energy, minimization, and dynamics 
calculations. J. Comput. Chem. 4: 187-217. 
Budin, N., Majeux, N., and Caflisch, A. 2001. Fragment-based 
flexible ligand docking by evolutionary optimization. 
Biol. Chem. 382: 1365-1372. 
Buxser, S., and Vroegop, S. 2005. Calculating the probability 
of detection for inhibitors in enzymatic or binding 
reactions in high-throughput screening. Anal. Biochem. 
340: 1-13. 
Cathers, B.E., Barrett, C., Palmer, J.T., and Rydzewski, R.M. 
2002. pH dependence of inhibitors targeting the occluding 
loop of cathepsin B. Bioorg. Chem. 30: 264-275. 
Cecchini, M., Kolb, P., Majeux, N., and Caflisch, A. 2004. 
Automated docking of highly flexible ligands by genetic 
algorithms: A critical assessment. J. Comput. Chem. 25: 
412-422. 
Cech, P., and Lehrer, R.I. 1984. Phagolysosomal pH of human 
neutrophils. Blood 63: 88-95. 
Cotrin, S.S., Puzer, L., Judice, W.A.D., Juliano, L., Carmona, 
A.K., and Juliano, M.A. 2004. Positional-scanning 
combinatorial libraries of fluorescence resonance energy 
transfer peptides to define substrate specificity of 
carboxydipeptidases: assays with human cathepsin B. Anal. 
Biochem. 335: 244-252. 
Friedrichs, B., Tepel, C., Reinheckel, T., Deussing, J., von 
Figura, K., Herzog, V., Peters, C., Saftig, P., and Brix, 
K. 2003. Thyroid functions of mouse cathepsins B, K, and 
L. J. Clin. Invest. 111: 1733-1745. 
Frlan, R., and Gobec, S. 2006. Inhibitors of cathepsin B. 
Curr. Med. Chem. 13: 2309-2327. 
Gu, F., and Gruenberg, J. 2000. ARF1 regulates pH-dependent 
COP functions in the early endocytic pathway. J. Biol. 
Chem. 275: 8154-8160. 
Hanada, K., Tamai, M., Yamagishi, M., Ohmura, S., Sawada, J., 
and Tanaka, I. 1978. Isolation and characterization of E-
64, a new thiol protease inhibitor. Agric. Biol. Chem. 
42: 523-528. 
 - 25 - 
Huang, D.Z., Lüthi, U., Kolb, P., Cecchini, M., Barberis, A., 
and Caflisch, A. 2006. In silico discovery of beta-
secretase inhibitors. J. Amer. Chem. Soc. 128: 5436-5443. 
Huang, D.Z., Lüthi, U., Kolb, P., Edler, K., Cecchini, M., 
Audetat, S., Barberis, A., and Caflisch, A. 2005. 
Discovery of cell-permeable non-peptide inhibitors of 
beta-secretase by high-throughput docking and continuum 
electrostatics calculations. J. Med. Chem. 48: 5108-5111. 
Illy, C., Quraishi, O., Wang, J., Purisima, E., Vernet, T., 
and Mort, J.S. 1997. Role of the occluding loop in 
cathepsin B activity. J. Biol. Chem. 272: 1197-1202. 
Im, W., Beglov, D., and Roux, B. 1998. Continuum solvation 
model: computation of electrostatic forces from numerical 
solutions to the Poisson-Boltzmann equation. Comput. 
Phys. Commun. 111: 59-75. 
Irwin, J.J., and Shoichet, B.K. 2005. ZINC - A free database 
of commercially available compounds for virtual 
screening. J. Chem. Inf. Model. 45: 177-182. 
Kolb, P., and Caflisch, A. 2006. Automatic and efficient 
decomposition of two-dimensional structures of small 
molecules for fragment-based high-throughput docking. J. 
Med. Chem. 49: 7384-7392. 
Kolb, P., Huang, D., Dey, F., and Caflisch, A. 2008. Discovery 
of kinase inhibitors by high-throughput docking and 
scoring based on a transferable linear interaction energy 
model. J. Med. Chem. 51: 1179-1188. 
Krupa, J.C., Hasnain, S., Nägler, D.K., Menard, R., and Mort, 
J.S. 2002. S '(2) substrate specificity and the role of 
His(110) and His(111) in the exopeptidase activity of 
human cathepsin B. Biochem. J. 361: 613-619. 
Kuhelj, R., Dolinar, M., Pungercar, J., and Turk, V. 1995. The 
preparation of catalytically active human cathepsin B 
from its precursor expressed in Escherichia coli in the 
form of inclusion bodies. Eur. J. Biochem. 229: 533-539. 
Kukor, Z., Mayerle, J., Krüger, B., Tóth, M., Steed, P.M., 
Halangk, W., Lerch, M.M., and Sahin-Tóth, M. 2002. 
Presence of cathepsin B in the human pancreatic secretory 
pathway and its role in trypsinogen activation during 
hereditary pancreatitis. J. Biol. Chem. 277: 21389-21396. 
 - 26 - 
Lenar•i•, B., Gabrijel•i•, D., Rozman, B., Drobni•-Košorok, 
M., and Turk, V. 1988. Human cathepsin B and cysteine 
proteinase inhibitors (CPIs) in inflammatory and 
metabolic joint diseases. Biol. Chem. Hoppe-Seyler 369: 
257-261. 
Majeux, N., Scarsi, M., Apostolakis, J., Ehrhardt, C., and 
Caflisch, A. 1999. Exhaustive docking of molecular 
fragments with electrostatic solvation. Proteins 37: 88-
105. 
Matsumoto, K., Mizoue, K., Kitamura, K., Tse, W.C., Huber, 
C.P., and Ishida, T. 1999. Structural basis of inhibition 
of cysteine proteases by E-64 and its derivatives. 
Biopolymers 51: 99-107. 
Matsunaga, Y., Saibara, T., Kido, H., and Katunuma, N. 1993. 
Participation of cathepsin B in processing of antigen 
presentation to MHC class II. FEBS Lett. 324: 325-330. 
McKay, M.J., Offermann, M.K., Barrett, A.J., and Bond, J.S. 
1983. Action of human liver cathepsin B on the oxidized 
insulin B chain. Biochem. J. 213: 467-471. 
Michaud, S., and Gour, B.J. 1998. Cathepsin B inhibitors as 
potential anti-metastatic agents. Expert Opin. Ther. Pat. 
8: 645-672. 
Mohamed, M.M., and Sloane, B.F. 2006. Cysteine cathepsins: 
multifunctional enzymes in cancer. Nat. Rev. Cancer 6: 
764-775. 
Momany, F.A., and Rone, R. 1992. Validation of the general 
purpose QUANTA ®3.2/CHARMm® force field. J. Comput. Chem. 
13: 888-900. 
Mort, J.S. 2004. Cathepsin B. In Handbook of proteolytic 
enzymes, 2nd ed. (eds. A.J. Barrett, N.D. Rawlings, and 
J.F. Woessner, Jr.), pp. 1079-1086. Elsevier, London. 
Mort, J.S., Magny, M.C., and Lee, E.R. 1998. Cathepsin B: an 
alternative protease for the generation of an aggrecan 
'metalloproteinase' cleavage neoepitope. Biochem. J. 335: 
491-494. 
Müntener, K., Zwicky, R., Csucs, G., and Baici, A. 2003. The 
alternative use of exons 2 and 3 in cathepsin B mRNA 
controls enzyme trafficking and triggers nuclear 
 - 27 - 
fragmentation in human cells. Histochem. Cell Biol. 119: 
93-101. 
Müntener, K., Zwicky, R., Csucs, G., Rohrer, J., and Baici, A. 
2004. Exon skipping of cathepsin B: mitochondrial 
targeting of a lysosomal peptidase provokes cell death. 
J. Biol. Chem. 279: 41012-41017. 
Murata, M., Miyashita, S., Yokoo, C., Tamai, M., Hanada, K., 
Hatayama, K., Towatari, T., Nikawa, T., and Katunuma, N. 
1991. Novel epoxysuccinyl peptides. Selective inhibitors 
of cathepsin B, in vitro. FEBS Lett. 280: 307-310. 
Musil, D., Zucic, D., Turk, D., Engh, R.A., Mayr, I., Huber, 
R., Popovic, T., Turk, V., Towatari, T., Katunuma, N., et 
al. 1991. The refined 2.15 Å X-ray crystal structure of 
human liver cathepsin B: the structural basis for its 
specificity. EMBO J. 10: 2321-2330. 
Nägler, D.K., Storer, A.C., Portaro, F.C.V., Carmona, E., 
Juliano, L., and Menard, R. 1997. Major increase in 
endopeptidase activity of human cathepsin B upon removal 
of occluding loop contacts. Biochemistry 36: 12608-12615. 
Nycander, M., Estrada, S., Mort, J.S., Abrahamson, M., and 
Björk, I. 1998. Two-step mechanism of inhibition of 
cathepsin B by cystatin c due to displacement of the 
proteinase occluding loop. FEBS Lett. 422: 61-64. 
Okamura-Oho, Y., Zhang, S.Q., Callahan, J.W., Murata, M., 
Oshima, A., and Suzuki, Y. 1997. Maturation and 
degradation of b-galactosidase in the post-Golgi 
compartment are regulated by cathepsin B and a non-
cysteine protease. FEBS Lett. 419: 231-234. 
Otto, H.H., and Schirmeister, T. 1997. Cysteine proteases and 
their inhibitors. Chem. Rev. 97: 133-171. 
Palmier, M.O., and Van Doren, S.R. 2007. Rapid determination 
of enzyme kinetics from fluorescence: Overcoming the 
inner filter effect. Anal. Biochem. 371: 43-51. 
Pavlova, A., Krupa, J.C., Mort, J.S., Abrahamson, M., and 
Björk, I. 2000. Cystatin inhibition of cathepsin B 
requires dislocation of the proteinase occluding loop. 
Demonstration by release of loop anchoring through 
mutation of His110. FEBS Lett. 487: 156-160. 
 - 28 - 
Quraishi, O., Nägler, D.K., Fox, T., Sivaraman, J., Cygler, 
M., Mort, J.S., and Storer, A.C. 1999. The occluding loop 
in cathepsin B defines the pH dependence of inhibition by 
its propeptide. Biochemistry 38: 5017-5023. 
Rawlings, N.D., Tolle, D.P., and Barrett, A.J. 2004. MEROPS: 
the peptidase database (http://merops.sanger.ac.uk). 
Nucleic Acids Res. 32 Database issue: D160-D164. 
Rofstad, E.K., Mathiesen, B., Kindem, K., and Galappathi, K. 
2006. Acidic extracellular pH promotes experimental 
metastasis of human melanoma cells in athymic nude mice. 
Cancer Res. 66: 6699-6707. 
Rowan, A.D., Feng, R., Konishi, Y., and Mort, J.S. 1993. 
Demonstration by electrospray mass spectrometry that the 
peptidylpeptidase activity of cathepsin B is capable of 
rat cathepsin B C-terminal processing. Biochem. J. 294: 
923-927. 
Schechter, I., and Berger, A. 1967. On the size of the active 
sites in proteases. I. Papain. Biochem. Biophys. Res. 
Commun. 27: 157-162. 
Schwabe, C. 1975. A fluorescence assay for proteolytic 
enzymes. Anal. Biochem. 53: 484-490. 
Selwyn, M.J. 1965. A simple test for inactivation of an enzyme 
during assay. Biochim. Biophys. Acta 105: 193-195. 
Shoichet, B.K. 2006. Screening in a spirit haunted world. Drug 
Discov. Today 11: 607-615. 
Takahashi, T., Dehdarani, A.H., Yonezawa, S., and Tang, J. 
1986. Porcine spleen cathepsin B is an exopeptidase. J. 
Biol. Chem. 261: 9375-9381. 
Turk, D., Podobnik, M., Kuhelj, R., Dolinar, M., and Turk, V. 
1996. Crystal structures of human procathepsin B at 3.2 
and 3.3 Angstroms resolution reveal an interaction motif 
between a papain-like cysteine protease and its 
propeptide. FEBS Lett. 384: 211-214. 
Yan, S.Q., and Sloane, B.F. 2003. Molecular regulation of 
human cathepsin B: Implication in pathologies. Biol. 
Chem. 384: 845-854. 
Zwicky, R., Müntener, K., Csucs, G., Goldring, M.B., and 
Baici, A. 2003. Exploring the role of 5'-alternative 
 - 29 - 
splicing and of the 3'-untranslated region of cathepsin B 
mRNA. Biol. Chem. 384: 1007-1018. 
 
 
 - 30 - 
Figure legends 
Figure 1. The occluding loop of human cathepsin B. A: closed 
conformation (red) in the mature enzyme (Musil et al. 1991), where a 
hydrogen bond is made between His110 and Asp22. The conformation seen 
in procathepsin B with the occluding loop lifted (green) to 
accommodate the propeptide, which is not shown for clarity (Turk et 
al. 1996). Image generated with PyMol software: DeLano, W.L, The 
PyMOL Molecular Graphics System (2002) DeLano Scientific, Palo Alto, 
CA, USA. http://www.pymol.org. B: scheme of the occluding loop with 
hydrogen bonds present in the closed conformation. The symbol Glyc 
attached to Asn113 indicates the N-linked oligosaccharide.  
 
Figure 2. Structure of the inhibitor. The IUPAC name of the compound 
is [2-[2-(2,4-dioxo-1,3-thiazolidin-3-yl)ethylamino]-2-oxoethyl] 2-
(furan-2-carbonylamino)acetate (abbreviated DOFA, Zinc-2005 Code: 
2616818). Numbering and lettering as help for the description in the 
main text. 
 
Figure 3. Kinetic models for the inhibition of cathepsin B. vi and v0 
represent reaction rates in the presence and in the absence of 
inhibitor, respectively. σ = [S]/K
m
; I90/10 = ratio of the inhibitor 
concentrations, which give 90% and 10% inhibition. The double-headed 
inhibitor possesses two distinct binding moieties that sequentially 
bind the enzyme. 
 
Figure 4. Inhibition profiles of human cathepsin B by DOFA. Main 
conditions and best-fit kinetic parameters are shown in the figures. 
A: inhibition profile using the FRET substrate Abz-GIVR↓AK(Dnp)-OH, 
pH = 4.5, [S] = K
m
 = 9.7 µM; data were obtained fluorimetrically with 
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λ
ex
/λ
em
 at 320/420 nm. The inset shows the specific velocity plot at 
four substrate and four inhibitor concentrations. B: inhibition 
profiles with Z-RR↓AMC as substrate; [S] = K
m
 = 0.47 mM at pH 6.0 
(black circles) and [S] = K
m
 = 1.54 mM at pH 4.5 (black squares). 
Data at pH = 6.0 were collected photometrically at 360 nm and those 
at pH = 4.5 were obtained fluorimetrically with λ
ex
/λ
em
 at 383/455 nm. 
Fluorescence readings in A and B were corrected for the inner filter 
effect. 
 
Figure 5. Ratios of inhibitor concentrations that give 90% and 10% 
inhibition. For Models 2 and 3 in Figure 3 the I90/10 ratio depends on 
a and σ = [S]/K
m
. Curves were generated with equations 4 and 6 shown 
in Figure 3. A: curves for Model 2, B: curves for Model 3. The black 
squares in panels A and B correspond to the best-fit value of the 
coefficient a, which coincides with the value obtained by inspection 
of the inhibition profiles at pH = 6.0 in Figure 4B. The black 
circle in panel B shows the best-fit value of the coefficient a 
(37), close to the value obtained by inspection of the inhibition 
profiles at pH = 4.5 in Figure 4B. 
 
Figure 6. Inhibition of cleavage of rabbit muscle fructose 1,6-
bisphosphate aldolase and of the bovine insulin β-chain by cathepsin 
B. Concentration-dependent inhibition by DOFA at pH 6.0. Released 
peptides were quantified fluorimetrically by the fluorescamine 
method. 
 
Figure 7. Proteolysis of rabbit muscle fructose 1,6-bisphosphate 
aldolase by cathepsin B. Aldolase was incubated 4 h at 25°C with 
cathepsin B at pH 6.0 and products were separated by SDS-PAGE. Lane 
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A: aldolase alone run in parallel as control; lane B: aldolase plus 
cathepsin B; lane C: aldolase with cathepsin B and DOFA. The N-
terminal and C-terminal parts of the rabbit aldolase sequence, with 
numbered amino acid residues, are shown on the top of the figure. 
Thin arrows indicate sequential peptidyl-dipeptidase cleavages by 
cathepsin B. The two open thick arrows show carboxypeptidase 
cleavages. The black thick arrow indicates a minor endoproteolytic 
attack site. Numbers on the left side indicate the molecular masses 
of markers in kDa. Numbers 1-4 with long pointing arrows are 
assigned to the bands for referencing in the main text, and the 
peptides identified within the bands are shown next to the band 
numbers. Peptides were identified in the excised bands by N-terminal 
sequencing and MALDI analysis. 
 
Figure 8. Proteolysis of the bovine insulin β-chain by cathepsin B. 
Incubation at pH 5.5 and 25°C in the absence (A) and in the presence 
(B) of DOFA. Peptides released by enzymatic digestion were 
characterized by LC/MALDI/MS. The sequence on the top of the figure 
shows the sequence of bovine insulin, β-chain with amino acid 
numbering. Boxed numbers, e.g. 6-28, indicate peptides released by 
the endo- and exoproteolytic action of cathepsin B. 
 
Figure 9. Stereo view of inhibitor and substrate within the 
structure of human cathepsin B. A: The protein surface is shown with 
the occluding loop in red, His110 and His111 in orange, and the 
catalytic Cys29 in yellow. The substrate (carbon atoms in purple) is 
shown as residues VR↓AK, which is part of the FRET substrate used in 
this study to monitor peptidyl-dipeptidase activity. The Dnp group, 
which is exposed to the solvent, was omitted for clarity. The pose 
of DOFA obtained by docking (carbon atoms in gray) is visible in the 
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upper part with the furan moiety in the occluding loop and the 
dioxothiazolidine ring sterically interfering with the lysine side 
chain of the substrate. B: Details of the presumed interactions 
between DOFA and cathepsin B residues (carbon atoms in green). The 
inhibitor makes three hydrogen bonds with residues of the occluding 
loop: carbonyl group labeled a in Figure 2 with amide nitrogen of 
Cys119, carbonyl group labeled b in Figure 2 with amide nitrogen of 
His111, and 2-oxo group of the dioxothiazolidine ring with Nδ1 of 
His110. The hydrogen bonds of the occluding loop in the closed 
conformation, His110-Asp22 and His111 with the C-terminal carbonyl of 
the substrate, are also shown. The red sphere indicates the position 
of a water molecule in the cathepsin B crystal structure. Images 
generated with PyMol software (see Figure 1). 
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